Loading...
Loading...
BMRN| Name | Value |
|---|---|
| Revenues | 594.6M |
| Cost of Revenue | 143.7M |
| Gross Profit | 450.9M |
| Operating Expense | 394.1M |
| Operating I/L | 56.8M |
| Other Income/Expense | 5.2M |
| Interest Income | 12.6M |
| Pretax | 70.8M |
| Income Tax Expense | 14.8M |
| Net Income/Loss | 56.0M |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for rare diseases and medical conditions. Its commercial products include enzyme replacement therapies for mucopolysaccharidosis, phenylketonuria, and ceroid lipofuscinosis, as well as a treatment for achondroplasia. The company also develops gene therapies for severe hemophilia A, PKU, and primary hyperoxaluria. BioMarin serves specialty pharmacies, hospitals, and international distributors. It generates revenue through the sale of its proprietary therapies and through license and collaboration agreements with other pharmaceutical companies.
